Ontwikkeling van nieuwe therapieën voor ischemische beroerte gericht op von Willebrand factor en fibrinolyse
Karakterisering en evaluatie van monoklonale antilichamen met differentiële effecten op de activatie van trombine activeerbare fibrinolyse inhibitor en karakterisering van nanobodies die de activiteit van het proenzyme stimuleren.
Structurele opheldering van antilichaam-gemedieerde modulering van thrombine-activeerbare fibrinolyse inhibitor.
Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not inflammation in rat models of direct and indirect acute lung injury
Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different invitro models
Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity
Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis